echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > How do the first crown brackets incorporated into the national harvest step by step to win?

    How do the first crown brackets incorporated into the national harvest step by step to win?

    • Last Update: 2020-10-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    01 The rise of the domestic coronary stent road coronary stent mainly experienced three stages, the improvement is mainly the following two aspects, one is the material of the stent itself, the other is the stent coated with drugs and loaded drug carriers.
    A stent made of metal, without any drug coating on the surface, easy to re-thrombosis after implantation, and foreign body retention;
    drug to remove the stent, is currently the most widely used stent.
    with the progress of technology, biodegradable support has become the focus of global stent enterprise research, of which Chinese enterprises occupy a considerable proportion.
    China's crown support technology started late, in a long time, Medtron, Boston Science, Johnson and Johnson and other imported brands occupy the leading position in China's crown bracket market, market share of more than 60%.
    nearly 20 years of development, the technical gap between domestic and imported crown support has been basically smoothed out.
    At present, domestic brands Lepu, minimally invascopic, Jiwei, Sano occupies nearly 70% of the domestic crown bracket market share, it can be said that in the field of crown vein bracket, "Made in China" out of a rising road.
    the same time, with the implementation of volume procurement, products face significant price reductions, to the high-end market-oriented importer price pressure is relatively large.
    and policy level, will also be more supportive of domestic enterprises, the future importers may gradually withdraw from the Chinese market.
    crown vein stent will be concentrated in innovative domestic leading enterprises, minimally invasional medical, Lepu Medical, Blue Fan Medical (Jiwei Medical), Sano Medical, Xinlitai five worlds of the new pattern is gradually emerging.
    02 domestic out of the country, Sano into a "black horse" domestic replacement process steadily advancing at the same time, the domestic crown bracket five giants will also target the world, accelerate the global sales layout of products.
    from the layout of the table, many people think that minimally invascope medical is a domestic crown support export to overseas markets leading enterprises.
    t really, otherwise.
    , china and the United States have a market size of more than 10 billion yuan.
    main profits from the European, American, Chinese and Japanese markets.
    micro-invassed medical coronary stents are only available in Europe and are not available in the United States, Japan or clinically.
    mainly concentrated in India, Brazil, Thailand and other countries.
    Take India as an example, India's crown bracket localization rate is 60%, forcing import bracket price cheap promotion, of which Abbott's Xience 1600 yuan / one, Medtron Resolut 1300 yuan / each, and Blue Sail Medical's BioFreedom 3300 yuan / one, it can be said that micro-invasive, blue sail and other Chinese crown bracket enterprises in India have no competitive advantage, relatively difficult to open the market.
    India stent import price comparison, the current Sano Medical drug elus coronary stent BuMA supreme (cobalt chromium alloy) after hundreds of international standards in line with the testing, verification and evaluation, has been reported in China, listed in Europe, clinical in the United States, Japan.
    and Sano Medical is currently the only Chinese cobalt chromium coronary stent company to be approved to conduct large-scale clinical trials in the United States and Japan.
    the company sold its products to Europe, while Sano sold them globally.
    the global layout, Sano Healthcare is expected to be a dark horse in the industry.
    03 strong enemy such as clouds, Sano Medical's breaking road Sano Medical since its infrasolation in 2007 has focused on the field of cardiovascular interventional treatment equipment, the main product is the heart stent.
    Sano Medical's heart stent products have covered 30 provinces and cities in China, more than 1,000 hospitals, a total of more than 600,000 implants.
    recent years, Sano Healthcare has performed well and achieved rapid revenue growth: from 260 million yuan to 435 million yuan in 2016-2019, with a compound annual growth rate of 18.7%.
    So there are micro-invasive, Lepu and other well-known domestic manufacturers, outside Abbott, Poco, Medtron and other world's top manufacturers, internal and external market competition, Sano Medical is how to break the game? 1, focus on the coronary stent field, hard strength product BuMA Supreme stent will soon be listed Sano Medical's business focus on coronary artery stent system and balloon expansion catheter two categories.
    2019 annual report shows that the company's bracket products sales revenue of 424 million yuan, revenue accounted for 84.40%.
    company's fist products BuMA bracket has an extremely superior performance advantage, has been 2 international patents and 7 domestic patents.
    at present, BuMA drug stent products have entered the country's 556 third-level hospitals for sale, of which 402 are Grade III A hospitals, accounting for about 60% of the country's PCI surgery of triple-A hospitals.
    BuMA Supreme Coronary Drug Escape Bracket System, the first high-end product in China to compete with the world's leading products in terms of quality, has a clear advantage in product design, coating process and clinical benefits.
    a cobalt-chromium bracket with a wall thickness of 80 microns.
    also has 80 per cent endo-skin coverage, significantly better than Abbott's latest generation of products, and is expected to significantly reduce the time it takes to take anticoagulants after surgery.
    of the industry will find that every technology iteration brings about changes in the market landscape.
    to the U.S. market: Sano Healthcare's BuMA Supreme bracket is on the market, and it's a bit like Abbott before 2008.
    's third-quarter 2008 report showed a 51 per cent rise in profits, largely due to a big outburst in the Xience bracket.
    in 2009, the Xience bracket accounted for more than 20% of the U.S. market share.
    wait until BuMA Supreme, which has the industry's leading technology edge, companies are successfully launched, and Sano Healthcare or Abbott's success in the crown bracket sector can quickly grab domestic and even international market share.
    2, continue to increase investment in research and development, with technological innovation to drive the future development since its inception, Sano Medical has continuously increased investment in scientific research, and strive to enhance the company's scientific research capacity, technical strength and industrialization level.
    understood that in 2019, Sano Medical research and development investment of 192 million yuan, accounting for 43.99 percent of operating income, an increase of 47.51 percent over the previous year.
    number of research and development personnel increased by 28.57 percent year-on-year.
    Even with the domestic medical device "one brother" called Meirui Medical, the overall research and development investment ratio is mostly maintained at about 10%, Sano medical research and development investment accounted for more than 40%, which means that Sano Medical will be almost half of the revenue into technology research and development.
    , Sano Medical attaches great importance to research and development.
    , its research and development investment has reached the cash stage, in the next 3-5 years, Sano Medical is expected to have a number of products in the study on the market.
    excellent products are complemented by continuous research and development investment, making Sano Healthcare a later leader in the industry.
    the future, look forward to Sano Medical can open up a broader market space!
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.